About PGDx

About PGDx

Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.

Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer.

PGDx was founded in 2010 by Luis Diaz and Victor Velculescu to help bring novel diagnostic approaches to patients with cancer. They are internationally recognized leaders in cancer genomics who have extensive experience in the application of innovative genomic technologies for drug development and clinical practice.

» Learn More

Our Philosophy

PGDx brings proprietary technology to each cancer genome analysis project and our CLIA-validated facility assures the highest specificity and sensitivity for your samples.

  • We approach every project and partnership through a comprehensive analysis of cancer genomes to seek out bona fide somatic mutations in cancer.

  • We strive to decipher the complexity of cancer by continually investing in our proprietary bioinformatics, filtering capabilities, and inspection approaches with a goal to accurately reveal sequence and structural alterations and important driver mutations found across multiple cancer types.

  • We instill a culture of teamwork and collaboration to empower our organization with speed, accuracy, adaptability, and innovation.


PGDx is CLIA certified and uses a validated process to assure the highest specificity and sensitivity for your samples. Review our certifications below.